E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma

Mina Maksimos; Barbara Muz; John L. Magnani; Abdel Kareem Azab

doi:10.1038/s41408-023-00828-4

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma

Mina Maksimos, Barbara Muz, John L. Magnani, Abdel Kareem Azab

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	48
Journal	Blood Cancer Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00828-4
State	Published - Dec 2023

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-023-00828-4

Cite this

@article{a1f192f84ec248339bc83587dd765d3e,

title = "E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma",

author = "Mina Maksimos and Barbara Muz and Magnani, {John L.} and Azab, {Abdel Kareem}",

note = "Funding Information: GMI-1930 lipid was provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092), and a grant from the Cancer Prevention & Research of Texas (CPRIT # RR220088). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. Special thanks to Prof. Erika Kothe, the Microbiology master program coordinator at the Friedrich Schiller University of Jena, for supervising Mina{\textquoteright}s work during his master{\textquoteright}s. Funding Information: GMI-1930 lipid was provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092), and a grant from the Cancer Prevention & Research of Texas (CPRIT # RR220088). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. Special thanks to Prof. Erika Kothe, the Microbiology master program coordinator at the Friedrich Schiller University of Jena, for supervising Mina{\textquoteright}s work during his master{\textquoteright}s. ",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00828-4",

language = "English (US)",

volume = "13",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma

AU - Maksimos, Mina

AU - Muz, Barbara

AU - Magnani, John L.

AU - Azab, Abdel Kareem

N1 - Funding Information: GMI-1930 lipid was provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092), and a grant from the Cancer Prevention & Research of Texas (CPRIT # RR220088). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. Special thanks to Prof. Erika Kothe, the Microbiology master program coordinator at the Friedrich Schiller University of Jena, for supervising Mina’s work during his master’s. Funding Information: GMI-1930 lipid was provided by GlycoMimetics Inc. (Rockville, MD). The study was supported partially by a research grant from GlycoMimetics, Inc. and by the award from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the National Cancer Institute of the NIH (U54CA199092), and a grant from the Cancer Prevention & Research of Texas (CPRIT # RR220088). The imaging studies were supported by NIH P50 CA094056 (Molecular Imaging Center) and NCI P30 CA091842 (Siteman Cancer Center Small Animal Cancer Imaging shared resource). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. Special thanks to Prof. Erika Kothe, the Microbiology master program coordinator at the Friedrich Schiller University of Jena, for supervising Mina’s work during his master’s.

PY - 2023/12

Y1 - 2023/12

UR - http://www.scopus.com/inward/record.url?scp=85152077902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152077902&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00828-4

DO - 10.1038/s41408-023-00828-4

M3 - Letter

C2 - 37029121

AN - SCOPUS:85152077902

SN - 2044-5385

VL - 13

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 48

ER -

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this